Antiphospholipid Syndrome
The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).
Drugs by status
Phase 4 trials (12)
Phase 2 trials (10)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (19)
- Bristol-Myers Squibb
- Bayer
- Hamilton Health Sciences Corporation
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Allegiance Health
- Mansoura University
- McGill University
- Tanta University
- University of Ottawa
- University of Adelaide
- University of Alberta
- Fudan University
- Zhejiang University
- Jiao Tong University
- University of Sao Paulo
- University of Paris
- University of Western Ontario
- Heart and Stroke Foundation of Canada
- Tongji University
Organization Involved with Phase 3 Indications (10)
Organization Involved with Phase 2 Indications (12)
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (4)